Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T14:56:40.942Z.
Calculation as of: 2026-10-06T14:56:40.942Z.
Quote observation: 2026-10-06T14:55:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e7bb4fe4bb3aa983eb4620adc8aa5d0f555a5020ff21ce65ee2b72f9631e0f85
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$2.81B
Price/FCF Ratio
35.60
TTM Avg
52.84
3Y Avg
87.29
5Y Avg
87.29
Market Cap
$2.69B
Price/FCF Ratio
N/A
TTM Avg
146.96
3Y Avg
80.20
5Y Avg
82.43
Market Cap
$2.69B
Price/FCF Ratio
16.97
TTM Avg
18.59
3Y Avg
43.84
5Y Avg
62.13
Market Cap
$2.67B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.06B
Price/FCF Ratio
N/A
TTM Avg
16.27
3Y Avg
21.05
5Y Avg
21.05
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | $2.87B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.81B | 35.60 | 52.84 | 87.29 | 87.29 |
| AtriCure, Inc. (ATRC)vs › | $2.78B | 54.27 | 72.35 | 93.08 | 93.08 |
| Enliven Therapeutics, Inc. (ELVN)vs › | $2.99B | N/A | N/A | N/A | N/A |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | N/A | 146.96 | 80.20 | 82.43 |
| Neogen Corporation (NEOG)vs › | $2.68B | N/A | 207.13 | 91.08 | 77.14 |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 16.97 | 18.59 | 43.84 | 62.13 |
| MBX Biosciences, Inc. Common Stock (MBX)vs › | $2.67B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | N/A | 16.27 | 21.05 | 21.05 |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.07B | N/A | 20.86 | 20.86 | 20.86 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
